🔗 Share this article

While the US proceeds with historic changes to its vaccination schedules, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by questioning Covid vaccinations in the global health crisis and has zeroed in on potential fatalities following Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Schedule

Health officials had intended to unveil radical revisions to the childhood immunization program in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a major change that would place the US out of alignment with much of the global community with little proof for benefit. The announcement has been pushed back until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to address the audience at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to head the division this year.

Consolidating Power at the Regulatory Body

This interim role might represent a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain childhood vaccine recommendations in the US so as to align more like the Danish model, a society with nationalized medicine and a population approximately the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Qualifications

The appointee has no obvious experience in medication creation, oversight or leadership, which has been typical for previous directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“It seems she lacks to have the necessary background” for leading the CDER, stated Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a major agency. She is not an expert in drug approvals.”

Former heads of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who led the center have had.”

CDER has an immense workload at the FDA, Woodcock pointed out.

“The public just zeroes in on the novel medication approvals, but the generic drug division clears numerous off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and other areas, and every single one need to be looked after,” she noted. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial management aspect to the role, which oversees more than 5,000 employees. “It is a enormous administrative position, if you perform it correctly,” the former official added.

Agency Reaction and Controversial Programs

When asked about questions about Høeg’s qualifications and whether this assignment represents increased cooperation among regulatory chiefs on vaccines, a spokesperson responded that the “inquiries rely on flawed presumptions”.

“Her resume is consistent with the responsibilities of her position,” the official said, noting the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s new expedited review system, a controversial rapid therapy clearance system that allegedly concerned her predecessors. “By what process are these drugs being selected for this voucher program? Who takes the decisions?” Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he stated, “the agency appears to be shifting towards less stringent rules of most medications, except for shots.”

Documented Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if problematic, history, critics observe. She released a analysis using non-validated public submissions to determine the frequency of myocarditis following COVID-19 vaccination. She advised the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the new federal leadership encompassed revising regulations for new vaccines and ending “non-essential” immunizations, she stated after the election on a audio program. At the FDA, Høeg has reportedly suggested preventing adolescent males from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the data in a extremely disingenuous, untruthful manner,” Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow dissenters, {like|